Positron emission tomography (PET) measures where a radiolabeled drug, biologic, nanoparticle, or cell therapy goes inside a living body. In non-human primate (NHP) studies, its main advantage is answering questions that terminal dissection can't: not just whether a candidate reaches its target, but where it travels, how far it spreads from the injection site, and how that pattern shifts over time.
Those questions matter most for vaccines and nanoparticle therapies, where the route through lymph nodes often determines how much antigen reaches the draining nodes and, in turn, how strong the immune response is.
A 2021 paper in Biomaterials showed what this looks like in practice. Martin and colleagues tracked a nanoparticle vaccine in rhesus macaques with PET plus tissue-level fluorescence imaging, working from the whole animal down to individual follicles. After a thigh injection, vaccine signal showed up in inguinal and iliac lymph nodes, some as far as 17 cm from the injection site. At the tissue level, the nanoparticle-displayed HIV envelope antigen had gathered around the follicular dendritic cell (FDC) networks inside B-cell follicles.
The takeaway for drug developers: imaging lets you connect what happens at the injection site to where the material ends up, without having to kill the animal at each time point to find out.
What Does PET Add to Biodistribution Studies?
Biodistribution work has always meant killing animals at set time points and then measuring the tissue: gamma counting, autoradiography, histology, or some bioanalytical readout. Each time point is a different animal, so you only ever get a snapshot.
Maximum Intensity Projections (MIPs) of *in vivo* PET scan at 24h showing 64Cu-DOTA-amph-CpG signal in macaques with region of interest highlighted. 'X' denotes injection site, red asterisks indicate fiducial markers.
PET removes that constraint. You can image the same animal repeatedly and watch the radiolabel move.
In preclinical work this single capability spills into several questions at once: where the material goes, how fast it clears, whether it reaches the target, and whether the distribution matches the proposed mechanism. For NHP studies in particular, the contrast with conventional tissue work looks like this:
|
Approach
|
Primary information
|
Major characteristic
|
|
PET imaging
|
Whole-body and regional biodistribution
|
Longitudinal, non-invasive
|
|
Ex vivo tissue analysis
|
Tissue concentration and molecular composition
|
Terminal, quantitative
|
|
Histology / immunohistochemistry
|
Tissue and cellular localization
|
High spatial resolution
|
|
Fluorescence imaging
|
Tissue-level distribution
|
High spatial resolution, usually ex vivo
|
|
MRI / CT
|
Anatomy and structural context
|
High anatomical resolution
|
PET isn't a stand-in for tissue analysis. Its value shows up when you pair the whole-body molecular picture with anatomy and tissue-level endpoints.
There is a scale trade-off to keep in mind. A whole-body scan resolves organs and large nodes, not individual follicles, and each image integrates signal over an acquisition window rather than freezing one instant. That limit is what makes the pairing below necessary: every method in the table covers a scale the others cannot reach.
A Rhesus Macaque Study of Lymphatic-Targeting Vaccines
Martin's group built a subunit vaccine meant to ride the lymphatics: an HIV envelope trimer mounted on a nanoparticle (trimer-NP), paired with a lipid-conjugated CpG adjuvant (amph-CpG). They used PET together with tissue fluorescence imaging to connect the whole-animal picture to what happened inside individual nodes.
After the thigh injection, PET picked up the vaccine mainly in inguinal and iliac nodes. Signal reached iliac nodes 17 cm from the injection site.
That distance matters. It shows you can't assume intramuscular drainage stops at the nearest node. In a large animal, the tracer crosses anatomically separate lymphatic stations that a standard local sample would miss. NHP PET earns its place in vaccine work here: it shows the actual extent of lymphatic spread in the living animal, instead of whatever nodes someone decided to collect ahead of time.
The study design also matters for anyone repeating it. The vaccine construct and the adjuvant were labeled in a way that made the two components visible in the same animal, which is what turns a distribution image into a statement about formulation behaviour rather than about radioactivity in general.
From Whole-Body Biodistribution to Lymph Node Microanatomy
The pairing of PET with tissue imaging is where this study gets interesting. PET set the macro pattern: inguinal and iliac nodes as the main uptake sites. Fluorescence imaging then showed how the vaccine components sat inside those nodes. The nanoparticle-displayed trimer had gathered around the edges of the FDC networks in B-cell follicles. That location makes biological sense: FDCs are the scaffold of the lymphoid follicle and the structure that holds antigen in the germinal center.
But the imaging doesn't prove cause. The study showed the antigen sitting next to FDC networks; it did not show, from PET alone, that this layout produced better B-cell immunity. Imaging tells you where the material is. Whether that location drives the immune response is a separate question, and you need immunological readouts to answer it.
The workflow chains together like this:
PET → regional distribution → tissue imaging → cellular location → immune or pharmacodynamic outcome
Each step adds what the previous one can't see on its own. Read backwards, the chain also shows where a program can go wrong: a strong PET signal with no tissue correlate usually means the label detached, and a tissue signal with no PET correlate usually means the scan missed the compartment.
Why the 17 cm Finding Matters for NHP Biodistribution Research
The 17 cm figure is the number everyone remembers from this paper, but it only means something in context.
The result came from one HIV vaccine, given in one site, in rhesus macaques. It is not a rule for how vaccines drain, and you shouldn't treat 17 cm as a fixed anatomical distance that holds across NHP studies. What it does show is that distant lymphatic uptake can be large, and that PET can measure it.
For anyone developing a vaccine, nanoparticle, or immunotherapy that travels through lymph, the finding raises a stack of practical questions: where does the material pool after injection, which nodes see the most, does the formulation change the pattern, and does that exposure line up with the immune or pharmacodynamic effect you actually want? PET answers the first few. Tissue and immune assays have to close the loop on the rest.
PET Is a Biodistribution Tool, Not a Standalone Efficacy Assay
A PET signal is not the same thing as activity. The camera sees the radionuclide, wherever it went: intact drug, a metabolite, a degraded fragment, or anything else still carrying the label. Which one you're looking at depends on how you labeled it.
So a PET biodistribution study needs company. A vaccine or nanoparticle program usually runs it alongside blood sampling for systemic PK, node sampling for tissue exposure, flow cytometry for immune-cell profiling, immunohistochemistry for location, and functional assays for the pharmacodynamic read. This matters most for biologics and nanoparticles, where the tracer and the active material don't always stay attached.
Chelator stability belongs in the same conversation. If the radiometal comes off the construct in circulation, the scan will show uptake in organs that have nothing to do with the drug, and the resulting image looks plausible enough to be believed.
Blood sampling is the cheapest control on that. If plasma radioactivity and the PET time course disagree, the scan is describing the label rather than the drug, and no amount of regions of interest will fix it.
Choosing a PET Radionuclide for NHP Biodistribution Studies
Pick the radionuclide to match how long the labeled molecule stays around and how it moves.
The common ones, 18F, 68Ga, 64Cu, 89Zr, and 124I, cover a wide range of physical half-lives. 18F decays in about 110 minutes, 64Cu in roughly 12.7 hours, 89Zr in about 3.27 days. Fast-moving small molecules suit the short-lived isotopes; antibodies, nanoparticles, and other slow biologics need the long-lived ones like 89Zr to stay imageable across the window you care about.
The practical constraint is the mismatch in time scales. A tracer that decays in two hours cannot describe a construct that takes three days to clear a compartment, and a tracer that lasts three days gives a blurred average of a process that finished on the first afternoon.
Match the isotope to the question first, then check that the labeling chemistry can actually deliver it at the specific activity the study needs.
Labeling also has to leave the molecule itself intact. Change its size, charge, lipophilicity, binding, or stability and you may change where it goes. Treat radiolabeling as study design, not a box to tick before the scan.
Why Use Non-Human Primates for Molecular Imaging?
NHPs sit between rodents and the clinic. They're big enough to scan on the same machines and protocols used in humans, and their anatomy is closer to ours than a mouse's.
Prisys' Biodistribution Imaging Service platform runs clinical-equivalent MRI, CT, PET-CT, and DSA, set up for repeated measures of disease progression, drug distribution, efficacy, and biomarkers. For molecular imaging, the payoff is being able to read PET against anatomy: PET/CT lines the signal up with structure, and MRI adds soft-tissue detail. The point of NHP imaging isn't the PET scan by itself. It's joining that image to NHP Pharmacology, bioanalysis, pathology, and the NHP(monkey) Disease Models behind the study.
Capabilities at Radio-labeling Facility
Body size is the other reason. A node that would be at the resolution limit in a mouse is a structure you can place and sample in a macaque, and the dose and volume you use are in the range a clinical protocol will later use.
Integrating PET Imaging into NHP Drug Development
A good NHP PET study starts from a question, not from "let's get a biodistribution image."
For a vaccine or nanoparticle, the workflow usually runs: label and QC the material, take a baseline scan if needed, administer, then acquire serial PET/CT, draw regions of interest, and finally tie the numbers to blood, tissue, and pharmacodynamic data. The dataset tells you whether the candidate reached the compartment it was meant for, and how exposure changed over time.
Imaging pulls its weight across the whole preclinical program: distribution, PK, target engagement, PD, efficacy, biomarkers. In NHPs the edge is longitudinal: you follow one animal through every time point instead of burning a new cohort for each scan. Terminal tissue work still earns its place when you need molecular or cellular resolution the camera can't give you.
Scheduling is part of the design as well. Scan times have to sit on the same clock as blood draws and tissue collections, or the comparison between modalities drifts by hours and the mismatch gets read as biology.
From Biodistribution to Translational Decision-Making
Reading PET data well means more than mapping where the drug went. The real question is whether the pattern matches the mechanism you designed for.
Take a vaccine built to hit draining lymph nodes. PET confirms the nodes actually got exposed. Tissue imaging shows where the antigen sits inside them. Immune assays say whether that location came with the B-cell, T-cell, or antibody response you wanted. The chain runs:
Administration → distribution → target-tissue exposure → cellular location → pharmacodynamic response → outcome
Break it anywhere and the story falls apart. A candidate can reach the right tissue without engaging the target, or pile up in tissue without doing anything useful. PET is one link in that chain, strong only when the pharmacology and tissue work are attached to it.
Conclusion
PET gives you a way to watch a drug move through a non-human primate over time, most useful when the distribution is too complex in space or time for terminal tissue collection to capture.
Martin's rhesus study is a clean example: PET showed vaccine uptake in inguinal and iliac nodes, out to 17 cm from the thigh shot, and tissue fluorescence placed the nanoparticle antigen around FDC networks in the follicles.
The lesson for developers is to read biodistribution as part of the full translational dataset, not as a standalone image. PET gives the longitudinal whole-body view; CT or MRI gives anatomy; tissue imaging resolves the local detail; PK/PD, immune, and pathology work decides what it means. For vaccines, nanoparticles, biologics, and cell therapies, that combination is what tells you how a candidate really behaves before it reaches the clinic.
References
Martin JT, Hartwell BL, Kumarapperuma SC, et al. Combined PET and whole-tissue imaging of lymphatic-targeting vaccines in non-human primates. Biomaterials. 2021;275:120868. doi:10.1016/j.biomaterials.2021.120868.
FAQ
Q: What is PET biodistribution imaging in NHP studies?
A: You label the drug, biologic, nanoparticle, or other test material with a positron emitter, then watch and measure where it goes in the living animal over time. It covers whole-body and regional distribution, and it works alongside terminal tissue analysis rather than replacing it.
Q: Why use PET imaging instead of conventional tissue collection?
A: Tissue collection measures the actual material, but each time point needs a different animal, so you only get snapshots. PET images the same animal again and again, giving you the time course instead of a series of disconnected samples.
Q: What did the rhesus macaque vaccine study demonstrate?
A: After a thigh shot, the lymphatic-targeting vaccine turned up mainly in inguinal and iliac nodes, with signal reaching iliac nodes 17 cm out. Tissue imaging placed the nanoparticle antigen around the FDC networks in B-cell follicles.
Q: Does PET imaging demonstrate target engagement or efficacy?
A: Not by itself. PET shows where the label went. Target engagement and efficacy need the molecular, cellular, functional, or pathological readouts to back them up.
Q: Which radionuclides can be used for PET biodistribution studies?
A: The usual set is 18F, 68Ga, 64Cu, 89Zr, and 124I. Pick based on how the candidate clears, how long you need to image, and what the labeling chemistry and tracer stability allow.
Q: Can PET be combined with other imaging modalities in NHP studies?
A: Yes. PET with CT or MRI adds the anatomy; tissue fluorescence, histology, or immunohistochemistry fill in local and cellular detail. Prisys' NHP platform offers PET-CT, MRI, CT, and DSA for this kind of translational work.
Related Reading
- Beyond Anatomy: Molecular Imaging in NHP Models For Translational Drug Development
- Molecular Imaging Biomarkers: Advancing Translational Research And Drug Development
- Why NHP Molecular Imaging Is Critical For Translational PET Studies
- What Is Molecular Imaging And Why Is It Important in Drug Development?
- NHP Radionuclide Biodistribution Studies: Molecular Imaging For Translational Drug Development













